Rosiglitazone out-performs Metformin and Glyburide in terms of renal function as an early-stage type 2 diabetes treatment


ADOPT (A Diabetes Outcomes Prevention Trial) showed that initial treatment with just rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. In CJASN, we examine the differences in albumin excretion, renal function and blood pressure over the course of 5 years between the treatment groups.

Patients were treated with rosiglitazone, metformin, or glyburide, and their albumin-creatinine ratio (ACR), glomerular filtration rate (GFR), and blood pressure were periodically measured. Over a 5-year period, initial treatment with rosiglitazone slowed the rise of ACR compared with metformin, preserved GFR compared with glyburide, and lowered blood pressure relative to both.